Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention.

Publication Type:

Journal Article


Current opinion in oncology, Volume 25, Issue 5, p.495-502 (2013)


2013, August 2013, Clinical Research Division, Public Health Sciences Division, Vaccine and Infectious Disease Division


The development of HIV protease inhibitors more than two decades ago heralded a new era in HIV care, changing the infection from universally fatal to chronic but controllable. With the widespread use of protease inhibitors, there was a reduction in the incidence and mortality of HIV-associated malignancies. Studies later found these drugs to have promising direct antitumor effects.